Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension

References

• Bakris GL, Weir M. (2000). Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160:685–693.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, Weber M, et al. (2011). The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 3:81–88
   Web of Science ®Google Scholar
• Cheung TT, Cheung BM. (2014). Managing blood pressure control in Asian patients: safety and efficacy of losartan. Clin Interv Aging 9:443–450
   PubMed Web of Science ®Google Scholar
• Granger C, McMurray J, Yusuf S, et al. CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362:772–776
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, de Zeeuw D, Thomas MC, et al. (2011). An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, Weldegiorgis M, Inker LA, et al. (2014). Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 63:244–250
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Clarke W, et al. Collaborative Study Group. (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. (2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:875–886
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, Task Force Members. (2013). 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Collaborators Developing The Japanese Equation for Estimated GFR. (2009). Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992
   PubMed Web of Science ®Google Scholar
• Ojima M, Igata H, Tanaka M, et al. (2011). In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 336:801–808
   PubMed Web of Science ®Google Scholar
• Okumura N, Hayashi M, Imai E, et al. (2012). Effects of carperitide on contrast-induced acute kidney injury with a minimum volume of contrast in chronic kidney disease patients. Nephron Extra 2:303–310
   PubMedGoogle Scholar
• Pahor M, Guralink JM, Corti MC, et al. (1995). Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 43:1191–1197
   PubMed Web of Science ®Google Scholar
• Rakugi H, Kario K, Enya K, et al. (2013). Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Pressure 22:22–28
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ando K, Fujita T, Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. (2014). The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37:253–392
   PubMed Web of Science ®Google Scholar
• Turgut F, Balogun RA, Abdel-Rahman EM. (2010). Renin–angiotensin–aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin J Am Soc Nephrol 5:1330–1339
   PubMed Web of Science ®Google Scholar
• Turgut F, Yesil Y, Balogun RA, Abdel-Rahman EM. (2013). Hypertension in the elderly: unique challenges and management. Clin Geriatr Med 29:593–609
   PubMed Web of Science ®Google Scholar
• Weir M, Rolfe M. (2010). Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5:531–548.
   PubMed Web of Science ®Google Scholar
• White WB, Weber MA, Sica D, et al.. (2011) Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57:413–420
   PubMed Web of Science ®Google Scholar
• Winkelmayer W, Zhang Z, Shahinfar S, et al. (2006). Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 29:2210–2217
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183
   PubMed Web of Science ®Google Scholar